Cara Therapeutics, Inc. (NASDAQ: CARA) released its financial results for the first quarter ended March 31, 2023, revealing revenues of $6.2 million, an increase of 29% compared to $4.8 million in Q1 2022.
Q1 2023 Financial Results
R&D expenses were $24.3 million for the three months ended March 31, 2023 compared to $21.3 million in the same period of 2022.
Other income, net was approximately $985,000 for the three months ended March 31, 2023 compared to approximately $162,000 in the same period of 2022.
Net loss was $26.7 million, or $(0.49) per basic and diluted share, compared to net loss of $27.7 million, or ($0.52) per basic and …